Introduction

One of the most fatal complications of hepatocellular carcinoma (HCC) is spontaneous tumor rupture; the incidence varies between 3% and 26% (1). HCC rupture is worldwide decreasing thanks to ultrasound screening, however it remains a significant health problem in Eastern Asia with mortality rates are as high as 25–100% (2). For resectable HCC ruptures, emergency hepatectomy or staged hepatectomy after transcatheter arterial embolization (TAE) are life-saving procedures, and efficient therapeutic methods (3). Associating liver partition and portal vein ligation (ALPPS) for HCC has been reported to be safe even in patients with portal vein tumor thrombosis (PVTT) (4,5).

We report a multimodal therapy including TAE, ALPPS and immunoglobulin infusion for a huge bleeding HCC with PVTT in hepatitis B virus (HBV) cirrhosis.

Case Report

Associating liver partition and portal vein ligation for bleeding hepatocellular carcinoma in HBV cirrhosis: a safety strategy

Giovanni Battista Levi Sandri, Giovanni Vennarecci, Pasquale Lepiane, Giuseppe Maria Ettorre

Division of General Surgery and Liver Transplantation, S. Camillo Hospital, Rome, Lazio, Italy

Correspondence to: Giovanni Battista Levi Sandri, M.D. Division of General Surgery and Liver Transplantation, S. Camillo Hospital, Circ.ne Gianicolense 87 00151 Rome, Lazio, Italy. Email: gblevisandri@gmail.com.

Abstract: The incidence of hepatocellular carcinoma (HCC) spontaneous tumor rupture varies between 3% and 26%. For resectable HCC ruptures, emergency hepatectomy or staged hepatectomy after transcatheter arterial embolization (TAE) are life-saving procedures, and efficient therapeutic methods. We report a multimodal therapy including TAE, associating liver partition and portal vein ligation (ALPPS) and immunoglobuline infusion for a huge bleeding HCC with portal vein tumor thrombosis (PVTT) in hepatitis B virus (HBV) cirrhosis. ALPPS first step began with an abdominal toilette due to the massive hemoperitoneum and a portal vein incision at the bifurcation of the right and left portal veins was performed. A freely floating left part of the thrombus was extracted from the left portal vein in order to restore the left portal vein. The right portal vein with complete thrombosis was closed. Liver partition was then performed. The second step was performed without complications. A HCC Edmondson grade 4 (pT3b) and a cirrhotic liver parenchyma were described. Postoperative ascites decompensation was treated and patient was discharged in postoperative day 21. The reported triple strategy allowed us to prolong patient live. A multimodal therapy including TAE, ALPPS and immunoglobuline is a good option for a life treatment in case of huge bleeding hepatocellular carcinoma with PVTT in HBV cirrhosis.

Keywords: Associating liver partition and portal vein ligation (ALPPS); hepatocellular carcinoma (HCC); arterial embolization; portal vein tumoral thrombosis; hepatitis B virus cirrhosis (HBV cirrhosis)

Received: 21 January 2017; Accepted: 13 February 2017; Published: 23 March 2017.

doi: 10.21037/tgh.2017.03.08

View this article at: http://dx.doi.org/10.21037/tgh.2017.03.08
the massive hemoperitoneum. Afterwards a mobilization of the huge HCC was necessary to control the hepatic hilum easily. A vessel loop was passed around left, right and portal vein trunk. A portal vein incision at the bifurcation of the right and left portal veins was performed. A freely floating left part of the thrombus was extracted from the left portal vein in order to restore the left portal vein. A 5/0 prolene left portal vein suture was done and portal flow was restore. A US-Doppler confirmed the correct left portal flow without presence of thrombosis. The right portal vein with complete thrombosis was closed. Liver partition was then performed. Postoperative first step CT confirmed the left portal vein patency (Figure 2A). Entecavir therapy was started since the first postoperative day with an intention to reduce the HBV DNA between the two surgical steps. The second step of ALPPS was performed 4 days after the first one. Surgery was uneventful. Pathological exam described a 90 mm ×70 mm ×50 mm nodule with multiple nodules in the right liver. A HCC Edmondson grade 4 (pT3b) and a cirrhotic liver parenchyma were described. Postoperative ascites decompensation (Figure 2B) was treated and patient was discharged in postoperative day 21.

First treatment in case of ruptured HCC is hemostasis. Staged hepatectomy after TAE decreases the mortality rate in these patients (6,7).

ALPPS for HCC has been successfully described as safe even in patient with PVTT and cirrhosis (6-9). Furthermore ALPPS for huge HCC has been reported without an increased risk of morbidity or mortality (10). In the reported case, a multimodal therapy was the winning strategy. As recommended a TAE was performed in order to control the HCC bleeding. One time the hemodynamic stability was obtained according with the high vascular risk with the PVTT an ALPPS procedure was planned. The first step was performed to have a vascular control and secure the left portal flow without which surgery would be useless. In addition to this we treated the HBV infection between the two steps. The second ALPPS step was a routinely one. The reported triple strategy allowed us to prolong patient live. Liver resection is associated with a longer survival outcome than non-surgical treatment in HCC patients with PVTT (11). Nevertheless, a Vp4 PVTT is a negative prognostic factor for patient survival and surgical resection remain debated (11).
In conclusion, a multimodal therapy including TAE, ALPPS and immunoglobuline is a good option for a life treatment in case of huge bleeding hepatocellular carcinoma with PVTT in HBV cirrhosis.

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Informed Consent: Written informed consent was obtained from the patients for publication of this manuscript and any accompanying images.

References


doi: 10.21037/tgh.2017.03.08